Harnessing the power of the placenta

Celularity’s unique technology realizes the full promise of cell therapies by harnessing the low-immunogenicity and regenerative properties of the postpartum placenta.

Why use postpartum placental-derived cells?

One of the biggest challenges cell therapy developers face is the human immune system—how do you make a cell-based treatment that the patient’s immune system does not reject as foreign?

Currently approved treatments overcome this challenge by using the patient’s own cells, autologous cell therapy, an approach that is extremely expensive and difficult to scale.

At Celularity, we start with a material that normally possess a low potential for provoking an immune response, the placenta, to develop allogeneic cell therapies that can be used without the need for matching the patient to the donor.

Then, using our proprietary technology, we convert a plentiful and normally discarded source material into potential therapeutics, with a single placenta capable of yielding 100 - 100,000+ doses, depending on the therapeutic.

Our technology makes it possible to develop cell therapies that are scalable and cost-effective, and that can accelerate preclinical development to as little as 18 - 24 months.


The Rapid Development Cycle Delivered by our IMPACT™ Platform

Our IMPACT™ (Immuno-Modulatory Placenta-derived Allogeneic Cell Therapy) platform is the foundation of a disruptive clinical development model that materially reduces the time- and cost to market for advanced cell therapies.

Anchored by a broad intellectual portfolio, the IMPACT™ platform has already produced a rich pipeline of products that are currently in clinical development for a range of indications in cancer and infectious diseases, and has longer term opportunities in inflammation and age-related diseases. Our demonstrated timeline from therapeutic discovery to Investigational New Drug (IND) application is less than 24 months.

The IMPACT™ platform is fueled by Celularity’s integrated, highly scalable supply chain, which extends from ethically-sourced and extensively screened and tested biomaterials through advanced cell manufacturing.

Highly Scalable Biosourcing and In-house GMP Manufacturing

We obtain ethically-sourced biomaterials through an extensive, established network. Donors and biomaterials are screened and tested to verify the lack of communicable diseases, and then processed in our state-of-the-art, 150,000 square-foot, GMP/ GTP facility.

Because our manufacturing process is highly modular, production is efficient, scalable, and reproducible.


At the hospital

  • Donor enrollment, qualification, selection, and informed consent
  • Biomaterial collection and testing

At our manufacturing facility

  • Proprietary cell harvesting and processing
  • Master cell bank establishment
  • Advanced cell manufacturing